infectious disease research is easy, safe, and economical with remote microsampling

Get instant access to our resource bundle and learn how others are using Mitra® devices with VAMS® technology and remote specimen collection to study SARS-CoV-2, influenza, and other infectious diseases, and the drugs that treat them.

Download Now
Infectious Disease Research Bundle

 

 

studies show that our microsampling devices are effective in infectious disease research

Our Infectious Disease Resource Bundle will help you easily adopt a new, remote approach to sample collection that enables research studies and clinical trials to occur at-home, in the field, or in locations without clinically trained staff. Mitra® devices with VAMS® technology provide simple precision for remote microsampling and efficient, automated lab processing. Learn how the National Institutes of Health (NIH), Swiss Tropical Institute, LGC Group, and other organizations are deploying remote microsampling with Mitra® devices globally.

Seroprevalence / Serosurveillance
Seroprevalence / Serosurveillance

Neutralizing Antibodies
Neutralizing Antibodies

Cytokines / Biomarkers
Cytokines / Biomarkers

Tropical Medicine Research
Tropical Medicine Research

Seroprevalence / Serosurveillance

Seroprevalence - SerosurveillanceSource/Credit: NIBIB/NIH. Nature Communications. Volume 12, Article number: 113 (2021) 

Mitra® remote microsampling devices are extremely well-suited for both small and large-scale serology studies. Research provided in our resource bundle illustrates:

  • > 99% Mitra sampling success rate in studies with thousands of remote participants
  • Assays compatible with Mitra samples with 100% sensitivity and 100% specificity with high confidence intervals
  • Ability to detect IgG, IgM, IgA from whole blood Mitra samples
  • Immunoassay methodology for Roche Elecsys®, Luminex, Quanterix Simoa®, and more  

Access our Resource Bundle for all these details plus insight into a multiplex assay that uses Mitra devices to simultaneously measure >30 strains of influenza.

 

Download Now

Neutralizing Antibodies

Neutralizing-AntibodiesCredit: Christopher Barnes and Pamela Bjorkman, California Institute of Technology, Pasadena.

Accurate measurement of antibody levels is critical for understanding both natural and vaccine-induced immunity. Antibody and immunity studies will inform "immunity passports," facilitating a return to school, work, and other activities. These studies benefit from remote microsampling. Mitra microsamples are quantitative and precise (RSD < 4%), enabling the reporting of specific titer levels. Data within our resource bundle shows:

  • Feasibility of using Mitra for measuring total IgG in a multi-plex assay
  • Very high correlations of Mitra samples to plasma/serum samples              nucleocapsid (R2 = 0.9957), RBD (R2 = 0.9929), & spike (R2 = 0.9918) proteins

Read all about this data and more in our Infectious Disease Research Resource Bundle and access the relevant literature for more insights.

Download Now

Cytokines / Biomarkers 

cytokines edited 2Credit: DropBio Pty Ltd (data provided as a courtesy prior to publication)

Researchers investigate cytokines and other biomarkers as early predictors of severe Covid-19 illness. They are hopeful at the prospect of earlier identification and intervention of patients at high risk for severe Covid-19 and other infections. Data included in our Resource Bundle illustrates that the following is possible with Mitra devices:

  • Quantification of 27 individual proteins from one Mitra sample, mostly cytokines and adipokines, using multiplex immunoassays and ELISAs for CRP and Leptin
  • Cytokines, including IL-6 and IL-1b, can be extracted and quantified from a single sample that has been self-collected by a study participant at home

Learn more by reading our news articles, including the one titled, cytokines as predictive biomarkers of severe COVID-19: could at-home sampling be helpful? 

 

Download Now

 

 

Tropical Medicine Research

MitraDuke4-528856-edited-1

Collecting biological specimens in low-resource areas to study tropical diseases is difficult and expensive. Mitra devices offer a convenient, reliable, and cost-effective solution to these issues. Mitra devices with VAMS tips also overcome the drying and analytical bias issues encountered with dried blood spot cards. Leading research institutions specializing in tropical medicine prefer Mitra collection for a variety of research projects, such as:

  • Pediatric study of voriconazole to treat fungal infections (≥ 94% recovery; 1 month stability @ -20°C)
  • PK study of albendazole for hookworm infected adolescents in Ivory Coast with strong correlation between plasma and Mitra samples 

Read our Infectious Disease Resource Bundle for additional insights on how to implement remote MItra microsampling in tropical medicine. 

Download Now

remote microsampling modernizes infectious disease research

As the Coronavirus Pandemic spread around the globe in 2020, we saw accelerated adoption of Mitra® devices and VAMS® technology for remote microsampling studies. With entire countries in lockdown, researchers realized it was time to fully embrace remote studies, decentralized trials, and virtual models. You can offer remote specimen collection to help people avoid exposure to contagions while they contribute to science. 

Download Now

why use microsampling to study diseases?

Leaders in infectious disease research use microsampling in innovative ways, from remote vaccine studies to drug trials for effective therapies.

Reliable Samples

  • Serology samples provide reliable data on previous exposure, antibodies & immunity
  • Mitra® devices deliver quality samples of precise volume (< 4% RSD)

User Friendly

  • Remote studies allow volunteers to participate safely and easily from home
  • Mitra® devices are easy to use: touch the tip to a drop of bio-fluid & it rapidly absorbs

Simple Logistics

  • During a crisis, you must gather & ship high-quality samples quickly and easily
  • Mitra® microsamples remain stable when mailed: no cold-shipping or freezer storage

Economical

  • No need to invest in new equipment for processing Mitra® microsamples
  • You save on shipping & processing costs: use standard 96-well format with Mitra®

Validated

  • Mitra® devices with VAMS® technology have been validated in 150+ published studies
  • VAMS® technology enables successful method development and accurate assays

Reliable Data

  • Volumetric microsampling on Mitra® devices generates precise & quantitative data
  • Devices and kits are labeled with scannable barcodes to ensure chain of custody

Mitra devices with VAMS technology deliver on the promise of microsampling with simplicity and precision ... Start your volumetric microsampling study today!
Download Now

we are proud of these microsampling leaders and innovators in infectious disease research

niaid_logo
stanford logo
FINAL LGC NEW LOGO - cmyk_Teal (1)
university of rochester - logo

hear what our customers say about Mitra® with VAMS® microsampling

In the US, use of the Mitra device is limited to research and non-diagnostic applications. In many countries outside the US, the Mitra device can be used as
a sample collection device for clinical diagnostic applications, as referenced in some content included here. 

The strong correlation between anti-RBD IgG and mAbs, combined with the demonstration in this study and by others that anti-RBD can reliably be measured from dried blood finger-prick samples, provides feasibility for future SARS-CoV-2 immunokinetic studies that incorporate RBD-IgG-based assays.”

— Alana Whitcombe, PhD candidate & scientist, Auckland University, New Zealand

The NIH ELISA-based serology protocol using Mitra® microsampling devices with VAMS® technology from Neoteryx gives all scientists a reliable method for identifying SARS-CoV-2 raised antibodies in blood microsamples with amazing specificity, which is critical during the coronavirus pandemic.”

— James Rudge, PhD, Technical Director, Neoteryx, USA  

Our COVID-19 assay is suitable for partnering with employers for back to work testing using the self-sampling Mitra® device, and therefore does not require a phlebotomist to take the blood sample in a healthcare setting.”

– Michael van der Merwe, Commercial Director, LGC, United Kingdom 

Researchers have considerable experience using these at-home blood collection kits to track the spread of other infectious diseases like influenza, and this method is safe, effective and easy-to-use. With a small finger-prick, volunteers can help scientists fight COVID-19 from their homes."

– Kaitlyn Sadtler, PhD, Study Lead and Section Chief, Immunoengineering at NIBIB, National Institutes of Heath (NIH)

"[During the pandemic] we haven't been able to collect samples in person for our studies, so remote microsampling has enabled us to run studies when we were otherwise shut down. It also enables us to collect longitudinal samples from a large number of subjects across a range of geographies."  

– Dr. Michael Snyder, The Snyder Lab, Stanford Medicine 

from decentralized research and clinical trials to remote monitoring, the future of specimen sampling is here

Safer, Simpler, Smarter, and More Convenient.

Download Our Infectious Disease Research Bundle!

Learn about the assays used, challenges overcome, and data gathered.

Neoteryx, LLC

421 Amapola Ave
Torrance, CA 90501
Call us: 1 (310) 787-8747
info@neoteryx.com

Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC. 

hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.  

Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.